Atropine sulfate

ApprovedSmall molecule

CCloudbreak Therapeutics, LLC

Atropine sulfate is one of 115 small molecule programs targeting Arrhythmia. It is currently in Approved.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArrhythmiaActive, not recruiting

PoisoningActive, not recruiting

MyopiaActive, not recruiting

DexmedetomidineCompleted

PapillomaActive, not recruiting

ArrhythmiaPreclinical

Active, not recruiting

PoisoningPhase 2/Phase 3

Active, not recruiting

MyopiaPhase 3

Active, not recruiting

DexmedetomidinePhase 2

Completed

PapillomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Papilloma

#DrugCompanyPhaseTrials

Atropine sulfate

CCloudbreak Therapeutics, LLC

Approved

1 2

Cervarix

GSK

Phase 3

9 3

GSK 257049

GSK

Phase 3

6 4

Comparator: Pbo

Merck & Co.

Phase 3

3 5

Gardasil

Merck & Co.

Phase 3

11 6

Havrix

GSK

Phase 3

1 7

Engerix-B

GSK

Phase 3

1 8

Keytruda

Merck & Co.

Phase 2

3 9

Taxol

Teva

Phase 2

2 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Myopia

NCT03690089

Q3 2027

Phase 2/3Not yet recruiting

Myopia

NCT07164092

Clinical

Trials by Indication[1]

Myopia3 trials

Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center

Not yet recruiting·MMansoura University·Phase 2/3·NCT07164092·45 enrolled

Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom

Active, not recruiting·BBelfast Health and Social Care Trust·Phase 2·NCT03690089·289 enrolled

Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children

Completed·OOcumension Therapeutics (Suzhou) Co., Ltd·Phase 3·NCT06697522·148 enrolled

Atropine3 trials

A Study of Inhaled Atropine Sulfate in Healthy Adults

Completed·MMicroDose Defense Products L.L.C.·Phase 1·NCT00947596·18 enrolled

Sublingual vs IV Atropine Bioavailability Study

Completed·BBiomedical Advanced Research and Development Authority·Phase 1·NCT04290039·15 enrolled

Pharmacokinetics of Atropine Oral Gel

Completed·UUniversity of Utah·Phase 1·NCT05164367·10 enrolled

Vomiting1 trial

Intrathecal Atropine vs IV Metoclopramide for Nausea & Vomiting During CS

Completed·MMansoura University·Phase 4·NCT03932578·60 enrolled

Caesarean Section1 trial

Intrathecal Levobupivacaine With Opioids for Caesarean Section

Completed·—·Phase 3·NCT01858090·93 enrolled

Clinical Trial1 trial

Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201

Completed·LLaboratorios Sophia S.A de C.V.·Phase 1·NCT05470881·29 enrolled

6 more indications

Adverse Events1 trial

Adverse Events Related to Low Dose Atropine

Completed·SScripps Health··NCT05683535·148 enrolled

Papilloma1 trial

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02858310·224 enrolled

Poisoning1 trial

Role of Intralipid in Management of Organophosphorus Poisoning

Withdrawn·AAmani Hassan Abdel-Wahab·Phase 2/3·NCT04393103

Arrhythmia1 trial

The Personalized Chinese Herb Formulas Over Hypertensive Bradyarrhythmia

Completed·JJun Xiao·N/A·NCT04505228·72 enrolled

Dexmedetomidine1 trial

Effect of Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose on Hemodynamic Changes During Laryngoscopy and Tracheal Intubation in Adults. A Randomized Comparative Study.

Completed·KKasr El Aini Hospital·Phase 2·NCT06327399·70 enrolled

Unspecified2 trials

Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution

Withdrawn·LLaboratorios Sophia S.A de C.V.·Phase 1·NCT05481489

Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop

Completed·CCloudbreak Therapeutics, LLC·Phase 1/2·NCT05372991·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Atropine sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atropine sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atropine sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cloudbreak Therapeutics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCloudbreak Therapeutics, LLC

Atropine sulfate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Myopia3 trials

Atropine3 trials

Vomiting1 trial

Caesarean Section1 trial

Clinical Trial1 trial

Adverse Events1 trial

Papilloma1 trial

Poisoning1 trial

Arrhythmia1 trial

Dexmedetomidine1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News